Catalent investing $2.5m in new China-based clinical supply facility
Catalent Pharma Solutions provides delivery technologies and development solutions. The company this week announced plans to invest $2.5m in a new clinical supply facility in Shanghai, China.
The facility, which will be Catalent’s second in China, is due to open in early 2019 and will have three controlled temperature rooms operating at 2-8°C, 15-25°C, and -20°C.
It also will offer returns and destruction services, as well as its FastChain supply services, including GMP secondary packaging, final assembly, labeling, and distribution of clinical supplies.
"The facility's location, outside of Shanghai’s Free Trade Zone, helps Catalent’s customers by providing easier importation into China for trials in the country. In providing a more efficient, timely way of getting supplies to where customers want them, it minimizes transit time and risk of excursions of limited-shelf life products," a Catalent spokesperson told us.
Catalent has an existing facility in Waigaoqiao, which opened in 2013 and provides Free Trade Zone (FTZ) access, among other services.
The spokesperson said, "more and more customers [are] doing global trials that include China, so having a pathway into China is important, as it helps Catalent provide China-based clients with our expertise in storage, distribution, packaging, and labeling."
